Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq:TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,400 shares of common stock to Lisa Schlesinger, Protara’s newly appointed Vice President, Head of New Product Development and Market Access.